NEW YORK — Oxford Cancer Analytics, a developer of liquid biopsy tests for early cancer detection, said Thursday that it has raised $11 million in a Series A financing round.
The round was led by We Venture Capital and Cross-Border Impact Ventures. It included existing investors Eka Ventures and Civilization Ventures, as well as new investors DigitalDx Ventures, Macmillan Cancer Support, Aurelium Ventures, OKG Capital, and unnamed angel investors.
Oxford Cancer Analytics uses proteomics and machine-learning technologies to identify and validate cancer biomarkers. Its lead product candidate is a protein-based blood test designed to identify signatures for high-risk lung cancer, according to the UK-based company. The new funding will be used to help commercialize the test.
The firm, which also has operations in Toronto, closed a $3.7 million financing round in early 2023.